ImmunityBio, Inc. (IBRX)
| Market Cap | 9.04B +341.3% |
| Revenue (ttm) | 165.79M +192.9% |
| Net Income | -992.36M |
| EPS | -0.99 |
| Shares Out | 1.06B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,360,305 |
| Open | 8.17 |
| Previous Close | 8.01 |
| Day's Range | 7.88 - 8.57 |
| 52-Week Range | 1.95 - 12.43 |
| Beta | 0.17 |
| Analysts | Strong Buy |
| Price Target | 14.25 (+67.06%) |
| Est. Earnings | Nov 17, 2026 |
About IBRX
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company’s platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and so... [Read more]
Financial Performance
In 2025, ImmunityBio's revenue was $113.29 million, an increase of 668.31% compared to the previous year's $14.75 million. Losses were -$351.40 million, -15.03% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for IBRX stock is "Strong Buy." The 12-month stock price target is $14.25, which is an increase of 67.06% from the latest price.
News
ImmunityBio announces first patients in Europe treated with ANKTIVA
ImmunityBio (IBRX) announced that the first patients in Europe received treatment with ANKTIVA in combination with Bacillus Calmette-Guerin, BCG, for BCG-unresponsive non-muscle invasive bladder cance...
ImmunityBio Announces First Patients in Europe Treated with ANKTIVA® Plus BCG for BCG-unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ
CULVER CITY, Calif. & DUBLIN--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the first patients in Europe received treatment with ANK...
ImmunityBio announces database lock for Cohort A of QUILT-2.005
ImmunityBio (IBRX) announced completion of the database lock for Cohort A of QUILT-2.005, its randomized, controlled, registrational trial evaluating ANKTIVA in combination with Bacillus Calmette-Guer...
ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), an immunotherapy company, today announced completion of the database lock for Cohort A of QUILT-2.005 (NCT02138734), its randomi...
ImmunityBio announces publication of long-term data from QUILT-3.032 study
ImmunityBio (IBRX) announced the publication of long-term data from the Phase 2/3 QUILT-3.032 study in the Journal of Urology. The study evaluated ANKTIVA in combination with Bacillus Calmette-Guerin ...
ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the publication of long-term data from the Phase 2/3 QUILT-3.032 study...
ImmunityBio price target raised to $14 from $12 at Jefferies
Jefferies raised the firm’s price target on ImmunityBio (IBRX) to $14 from $12 and keeps a Buy rating on the shares after the FDA expanded the approved indication for Anktiva…
ImmunityBio says FDA expands approval indication for ANKTIVA-BCG combo
ImmunityBio (IBRX) announced that the U.S. Food and Drug Administration has expanded the approved indication for ANKTIVA in combination with Bacillus Calmette-Guerin to include patients with BCG-unres...
FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has expanded the appr...
ImmunityBio price target raised to $16 from $12 at Piper Sandler
Piper Sandler raised the firm’s price target on ImmunityBio (IBRX) to $16 from $12 and keeps an Overweight rating on the shares.
ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that Dr. Patrick Soon-Shiong, its Founder, Executive Chairman and Glob...
ImmunityBio put volume heavy and directionally bearish
Bearish flow noted in ImmunityBio (IBRX) with 14,599 puts trading, or 7x expected. Most active are Jan-27 9 puts and 10/2 weekly 7 puts, with total volume in those strikes…
ImmunityBio appoints Kim as Vice Chairman
ImmunityBio (IBRX) announced that Dr. Jim Yong Kim has joined the company as Vice Chairman. Dr. Kim will serve in a newly created Office of the Executive Chairman, where he…
ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that Dr. Jim Yong Kim has joined the company as Vice Chairman. Dr. Kim...
ImmunityBio reports Q2 EPS (22c) vs. (10c) last year
Reports Q2 revenue $51.2M, consensus $49.7M. “Our record quarterly net product revenue of $50.7 million and eighth consecutive quarter of sequential growth reflect continued physician adoption of ANKT...
ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage biotechnology company, today announced financial and operational results for the second quarter ended June 30...
ImmunityBio Earnings release: Q2 2026
ImmunityBio released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
ImmunityBio Quarterly report: Q2 2026
ImmunityBio has published its Q2 2026 quarterly earnings report on August 4, 2026.
ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated commercial-stage biotechnology company, today announced that the Emirates Drug Establishment (EDE) of th...
ImmunityBio Transcript: AGM 2026
The meeting re-elected all nine incumbent directors and ratified Deloitte & Touche LLP as auditor for 2026. No shareholder questions or additional nominations were received, and voting results will be reported to the SEC.
ImmunityBio Transcript: Jefferies Global Healthcare Conference 2026
The conference highlighted robust clinical and commercial progress for ANKTIVA, with strong efficacy and durability in bladder and lung cancer, expanding global approvals, and a growing pipeline. Financials remain solid, and new BCG strains aim to resolve shortages. Patient outcomes and physician feedback underscore transformative impact.